PomDoctor Limited filed a Form 6-K with the SEC on November 2, 2026, disclosing receipt of two Nasdaq deficiency letters on October 28, 2026, related to failures to meet minimum market value of listed securities and market value of publicly held shares requirements.

Key Highlights

  • Two deficiency letters received: Nasdaq's Listing Qualifications Department notified PomDoctor Limited on October 28, 2026, of deficiencies under Nasdaq Listing Rules 5450(b)(2)(A) and 5450(b)(2&3)(C).
  • MVLS shortfall: The company's market value of listed securities fell below the required $50 million threshold for 30 consecutive business days from September 16, 2026 through October 27, 2026.
  • MVPHS shortfall: The company's market value of publicly held shares fell below the required $15 million threshold for the same 30 consecutive business day period.
  • Compliance deadline: The company has 180 calendar days, or until April 26, 2027, to regain compliance with both requirements.
  • Path to compliance: Nasdaq will confirm compliance if MVLS closes at $50 million or more, and MVPHS closes at $15 million or more, each for a minimum of ten consecutive business days during the compliance period.
  • Delisting risk: The company stated "there can be no assurance that the Company will regain compliance" within the compliance period.

PomDoctor Discloses Nasdaq Listing Deficiencies Tied to Market Value Metrics

According to the filing, PomDoctor Limited (NASDAQ:POM) received two letters from Nasdaq's Listing Qualifications Department on October 28, 2026. The first letter addressed the company's failure to meet the market value of listed securities requirement under Nasdaq Listing Rule 5450(b)(2)(A), which mandates a minimum MVLS of $50 million. The Staff noted that the company also does not meet the requirements under Nasdaq Listing Rule 5450(b)(3)(A). The measurement period cited was 30 consecutive business days from September 16, 2026 through October 27, 2026.

The second letter, also covering the same 30-consecutive-business-day window, notified the company of a deficiency under Nasdaq Listing Rule 5450(b)(2&3)(C), which requires a minimum market value of publicly held shares of $15 million. Pursuant to Nasdaq Listing Rule 5810(c)(3)(D), the company has the same 180-calendar-day compliance period, expiring April 26, 2027, to address this deficiency. For both requirements, Nasdaq has indicated it will provide written confirmation of compliance if the applicable threshold is met for at least ten consecutive business days during the compliance window.

The filing states that if the company does not regain compliance before the end of either applicable compliance period, it "will receive written notification that its securities are subject to delisting," at which point the company may appeal to a Hearings Panel. The company disclosed it "intends to monitor its MVLS and MVPHS and evaluate available options to regain compliance." The Form 6-K was signed by Zhenyang Shi, Chairman and Chief Executive Officer, and a press release dated November 2, 2026, was furnished as Exhibit 99.1.

What Was Disclosed

PomDoctor Limited reported receipt of two Nasdaq deficiency notices on October 28, 2026, for failing to maintain minimum market value of listed securities of $50 million and minimum market value of publicly held shares of $15 million, with a compliance deadline of April 26, 2027 for both.